Jia-Wey Tu
Overview
Explore the profile of Jia-Wey Tu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
15
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
On J, Ghaderi S, Rittmann C, Hoffmann G, Gier F, Woloschin V, et al.
Int J Mol Sci
. 2025 Feb;
26(3).
PMID: 39940844
Triple-negative breast cancer (TNBC) represents the most aggressive breast carcinoma subtype lacking efficient therapeutic options. A promising approach in cancer treatment is the pharmacological inhibition of murine double minute 2...
2.
Fischer F, Schliehe-Diecks J, Tu J, Gangnus T, Ho Y, Hebeis M, et al.
J Med Chem
. 2024 Nov;
67(23):21223-21250.
PMID: 39602240
Histone deacetylase inhibitors (HDACi) are established anticancer drugs, especially in hematological cancers. This study aimed to design, synthesize, and evaluate a set of HDACi featuring a pentyloxyamide connecting unit linker...
3.
Tretbar M, Schliehe-Diecks J, von Bredow L, Tan K, Roatsch M, Tu J, et al.
Eur J Med Chem
. 2024 May;
272:116447.
PMID: 38714044
Histone deacetylase 6 (HDAC6) is an emerging drug target to treat oncological and non-oncological conditions. Since highly selective HDAC6 inhibitors display limited anticancer activity when used as single agent, they...
4.
Vogt M, Dienstbier N, Schliehe-Diecks J, Scharov K, Tu J, Gebing P, et al.
Cell Death Dis
. 2023 Dec;
14(12):799.
PMID: 38057328
HSP90 has emerged as an appealing anti-cancer target. However, HSP90 inhibitors (HSP90i) are characterized by limited clinical utility, primarily due to the resistance acquisition via heat shock response (HSR) induction....
5.
Oikonomou A, Valsecchi L, Quadri M, Watrin T, Scharov K, Procopio S, et al.
Biochem Pharmacol
. 2023 Sep;
217:115809.
PMID: 37717691
Although a great cure rate has been achieved for pediatric BCP-ALL, approximately 15% of patients do not respond to conventional chemotherapy and experience disease relapse. A major effort to improve...
6.
Fazio G, Bresolin S, Silvestri D, Quadri M, Saitta C, Vendramini E, et al.
EBioMedicine
. 2022 Aug;
83:104224.
PMID: 35985167
Background: Despite intensive risk-based treatment protocols, 15% of paediatric patients with B-Cell Precursor Acute Lymphoblastic Leukaemia (BCP-ALL) experience relapse. There is urgent need of novel strategies to target poor prognosis...